Key Takeaways for Selling a Premier Practice in 2026
- Selling a premier dental practice to a DSO in 2026 is a high-stakes, one-time event where buyers usually have far more experience than sellers.
- A dedicated, dental-specific sell-side advisor can level the playing field by shaping the EBITDA story and running a competitive bid process that produces multiple offers.
- CPA-led, diligence-grade valuations can help protect sellers from post-LOI price cuts that often follow free or buyer-supplied estimates.
- McLerran & Associates reports approximately 30% higher valuations and an 85–90% transaction success rate, based on careful buyer vetting and active value defense through closing.
- Schedule a free, confidential discovery call with McLerran & Associates to see what your practice may be worth in today’s market.
How to Hire a Dental-Specific Advisor in 7 Steps
Use these 7 checkpoints before you sign any engagement letter with a sell-side advisor.
- Dental-only focus. Confirm the firm works only in dental, not across multiple healthcare or general business categories.
- Verified transaction volume. Ask for the number of dental practice sales closed in the past 24 months, broken out by solo, group, and DSO-track deals.
- Named buyer relationships. Request specific DSO and private equity buyer names, and ask why each buyer belongs on the outreach list.
- Senior accountability. Confirm a named senior advisor will run your process through negotiation and diligence, instead of handing it off to junior staff.
- Valuation quality. Require a CPA-led, diligence-grade EBITDA analysis, not a quick free estimate that may collapse under buyer review.
- Competitive process structure. Verify the firm runs an auction-style bid process that aims for multiple offers, not a single-buyer introduction.
- Seller references. Speak with at least 3 dentists whose sales closed in the past 18 months and ask detailed questions about their experience.
Side-by-Side Advisor Comparison: 2026
The table below highlights how McLerran & Associates’ dental-specific model compares with going it alone, using a local broker, or hiring a multi-vertical advisor across factors that can shape your final outcome.
| Dimension | DIY / FSBO | Local Generalist Broker | Multi-Vertical Advisor | McLerran & Associates |
|---|---|---|---|---|
| Dental specialization | None | Local only | Spread across verticals | Dental-only, national depth |
| Both sale paths (private buyer & DSO) | No | Usually one | Sometimes | Both, roughly half and half |
| Valuation quality | Buyer-set | Weak | Variable | CPA-led, diligence-grade |
| Buyer pool | One buyer | 1–2 DSOs | Generic list | Largest vetted premier pool, poorly run DSOs blacklisted |
| Transaction rate | 15–20% | Below average | Variable | 85–90% vs. 35–40% industry norm |
| Valuation lift vs. going it alone | Baseline | Minimal | Some | 30% average lift |
Transaction rate and valuation lift figures reflect McLerran & Associates' internal aggregate data across approximately 2,000 completed practice sales. Industry norm figures are drawn from publicly available broker benchmarks.
Choosing Between Private Buyer and DSO Affiliation
The first step in any transition is knowing which paths are realistic for your practice and what each path may be worth to you. Two main routes usually exist: a doctor-to-doctor sale to a private buyer or an affiliation with a DSO or private-equity-backed platform.
For practices generating roughly $1M–$1.5M in annual revenue, a doctor-to-doctor sale often fits naturally. For practices at $1.5M and above, DSO affiliation becomes a serious option, and for the largest practices, it can sometimes be the higher-value route. Dentistry was approximately one-third consolidated as of mid-2026, and demand for premier, Class A practices remained near all-time highs.
That sustained buyer demand can create real flexibility for mid-sized practices. Owners in the $1.5M–$3M revenue range, what McLerran & Associates calls the “Venn diagram middle,” can often go either direction. A side-by-side valuation that shows your practice’s value in both markets can support a confident choice. Because McLerran works both paths in roughly equal measure, it can present that comparison instead of steering you toward the lane that benefits the advisor.
Schedule a free, confidential discovery call with McLerran & Associates to receive a side-by-side valuation of your practice across both transition paths.
Creating Real Buyer Competition
A strong sell-side advisor creates competition among buyers, which can be one of the main drivers of higher outcomes. A practice owner who negotiates directly with one DSO has little leverage, because the buyer knows it is the only bidder and can price accordingly. A structured, auction-style process changes that dynamic.
McLerran & Associates typically runs a 45–60 day competitive bid process that often produces around 10 offers per listing from a vetted pool of qualified DSO and private equity buyers. The team removes poorly run or undercapitalized DSOs before the process starts, so owners see only buyers worth serious consideration. That advisor-led competition can materially improve total transaction value compared with an unsolicited, one-off offer.
In recent surveys, 69% of DSOs expected their private equity sponsors to drive a moderate or high increase in acquisition activity in 2026, and 78% anticipated recapitalization within 12 to 36 months. Those conditions can favor sellers who enter the market with a planned, competitive process instead of reacting to the first inbound call. McLerran focuses on selling practices, not just listing them.
CPA-Led EBITDA Valuation vs. Free “Napkin Math”
A “free” valuation usually serves as a lead-generation tool, not a full analysis. The buyer or broker sets a rough number that becomes the anchor for every later conversation. During due diligence, the buyer’s team reviews that number line by line. Weak analysis often leads to a “re-trade,” where the buyer lowers the price after you have already invested months in the process.
McLerran & Associates builds a CPA-led EBITDA analysis from the ground up. The team unpacks every discretionary, personal, and non-recurring expense, often called “add-backs,” to reach true, normalized profitability. A dental practice’s transaction value can vary significantly depending on whether the seller runs a prepared, competitive process or a reactive sale. Diligence-grade work can often pay for itself many times over by reducing the risk of late-stage price cuts.
In one documented case, a free valuation placed a practice at $2.5M. McLerran valued the same practice at $4.5M, and it ultimately sold for $5.25M after a competitive process.
Vetting DSOs and Finding the Right Partner
Not every DSO makes a good long-term partner for a premier practice. DSO acquisition activity remained brisk in 2025 and 2026, with hundreds of U.S. dental practice affiliations each year, yet buyer quality can vary widely. Careful buyer vetting sits at the center of McLerran’s role.
A well-backed DSO buyer typically shows a consistent pattern across several areas that together support a more stable outcome:
- Profitable operations across its existing portfolio, not just at the practice being acquired
- Experienced management with a history of successful affiliations and integrations
- A private equity sponsor with relevant healthcare deal experience and a clear investment thesis
- Positive feedback from prior sellers and evidence of stable post-close environments
- Sufficient financial strength to honor equity commitments at a future recapitalization
An undercapitalized or poorly run DSO may present an attractive headline price but carry risks that can erode the value of the equity portion of your deal, which can represent 10–30% of total consideration. McLerran aims to steer clients toward well-backed buyers and away from groups known for difficult post-close experiences.
Modeling Cash, Equity, and Earnout Over Time
Most DSO deals use a mix of cash, equity, and earnout, which can behave very differently over time. A typical DSO affiliation allocates roughly 60–75% of total consideration as cash at close, 10–30% as equity rollover, and the remainder as an earnout tied to post-closing performance targets. Each piece has its own tax treatment. Much of a DSO deal structured as a sale of goodwill may qualify for long-term capital gains rates instead of ordinary income rates. Your tax advisor can provide guidance for your specific situation.
McLerran models each proposed structure across 3-, 5-, 7-, and 10-year horizons and usually assumes one recapitalization in years 5–7. That modeling focuses on the practical question most sellers care about: what this deal may net after taxes across the full life of the transaction and how that compares with keeping the practice.
Several key variables work together in that model:
- Cash at close and its immediate after-tax value
- Equity held at the joint-venture level, which may pay distributions but have a lower ceiling, versus the holding-company level, which may skip distributions but offer a higher ceiling
- Earnout terms, including whether provisions are pro-rata, where a near-miss still pays most of the earnout, or binary
- The DSO’s projected growth path and recapitalization timeline, which can influence equity value
How McLerran Helps Maximize Your Outcome
McLerran & Associates reports that its clients see approximately 30% higher valuations on average than owners who sell on their own. That lift reflects the combined effect of diligence-grade valuation work, a structured competitive bid process, and active defense of quality-of-earnings through closing. When a buyer’s diligence team attempts to re-trade the agreed price, McLerran works to defend the EBITDA it underwrote and reminds buyers that other vetted bidders remain in the wings.
The firm’s aggregate track record includes approximately 2,000 successful practice sales, roughly $2 billion in closed transaction volume, and more than 10,000 practices evaluated, with a transaction rate reported at 85–90% compared with an industry norm closer to 35–40%. The McLerran M&A Summit (October 29–30, 2026) offers owners a low-pressure way to learn more, including a complimentary $2,500 practice valuation and 4 CE credits.
Schedule a free, confidential discovery call with McLerran & Associates or call (512) 900-7989 to speak with an advisor directly.
Frequently Asked Questions
What valuation multiple can I expect for my dental practice in 2026?
Multiples in 2026 can vary based on practice size, specialty, payer mix, provider structure, and geography, and buyers usually apply them to normalized EBITDA, not gross revenue. Larger practices with associate-driven production, diversified payer mix, and strong hygiene programs often command higher multiples than smaller, owner-dependent practices. Specialty practices generally trade at higher ranges than general dentistry, though the specific premium can depend on referral patterns, procedure mix, and buyer competition in your area. Your actual multiple comes from your specific numbers, which a CPA-led valuation can quantify. Practices with significant Medicaid revenue may see some multiple compression because of reimbursement risk. Any multiple quoted before a full analysis should be viewed as directional, not a firm commitment.
Do I have to keep working after I sell to a DSO?
Most DSO affiliations expect the selling doctor to keep working for a period after closing. A minimum 5-year post-close employment agreement is common, although terms can vary by buyer and deal structure. Some deals allow a shorter work-back if the owner has already reduced clinical hours significantly. On a doctor-to-doctor walk-away sale, the work-back period usually runs 4–8 weeks. Clarifying and negotiating your post-close obligations forms a core part of a sell-side advisor’s work. A good advisor aims to align those terms with your actual timeline and goals instead of accepting a standard template that mainly benefits the buyer.
How do I tell a well-backed DSO from an undercapitalized one?
Vetting buyers means looking beyond the headline price and into the strength of the platform. Signs of a well-backed DSO can include profitability across its existing portfolio, an experienced management team with a record of successful affiliations, a private equity sponsor with relevant healthcare experience, and positive feedback from prior sellers. Red flags can include heavy debt relative to cash flow, rapid expansion without adequate operational infrastructure, and reluctance to provide references from selling dentists. Because 30% or more of your deal consideration may sit in equity, you are effectively buying stock in the DSO, so it deserves careful review. McLerran screens buyers before they reach the table and has blacklisted DSOs known for poor post-close environments.
Why is a paid valuation better than a free one?
A free valuation usually serves as a marketing tool and often relies on a rough estimate that has not been tested against the add-backs and adjustments a buyer’s diligence team will review. Once that estimate reaches due diligence, buyers may challenge it and push the price down. A CPA-led, diligence-grade valuation is built in the same way a buyer’s quality-of-earnings team will test it, with every add-back documented and each adjustment supported. That preparation can help keep the agreed price from eroding between LOI and closing. In many cases, the cost of a rigorous valuation represents a small fraction of the value it can help protect.
Is 2026 a good time to sell a premier dental practice?
Demand for Class A, premier dental practices remains near historic highs in 2026, with DSO acquisition activity brisk and private equity sponsors actively redeploying capital. The market, however, is not uniform. Practices with strong payer mix, associate-driven production, and solid hygiene programs tend to attract the most competitive offers, while practices with heavy Medicaid exposure or high owner dependence often see more conservative valuations. The most accurate answer for your practice comes from a current valuation and a candid view of how buyers are likely to underwrite your numbers. McLerran can explain where you stand today, and if you are not ready to sell, the firm can update your valuation at no charge a year later instead of pushing you into a deal that does not fit.
Conclusion: Turning a One-Time Sale into a Well-Informed Decision
Selling a premier dental practice in 2026 against sophisticated DSO buyers usually requires more than a simple listing. A dental-specific sell-side advisor can help control the EBITDA narrative, create competition among vetted buyers, and defend your valuation through closing. With a long track record of completed sales, significant transaction volume, and a reported transaction rate well above industry norms, McLerran & Associates positions itself as a leading dental-specific sell-side M&A advisory firm for owners who want to be deliberate about their outcome.
Schedule a free, confidential discovery call with McLerran & Associates, call (512) 900-7989, email info@dentaltransitions.com, or visit dentaltransitions.com/contact-us.
